English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Reveromycin A (Rev.A) is an inhibitor of epidermal growth factor-dependent cell growth that is produced from the culture broth of an actinomycete strain. Rev.A was assessed for its ability to regulate antigen (Ag) presentation by A20-HL B lymphoma cells bearing trinitrophenyl (TNP)-specific surface IgM (sIgM) to cloned T cells specific for OVA(323-339)/I-Ad. Rev.A-treatment inhibited the presentation of Ag internalized via sIgM, but not of Ag via fluid-phase pinocytosis. Rev.A-treatment decreased protein synthesis, but a similar decrease in protein synthesis by cycloheximide induced much less inhibition of sIgM-mediated Ag presentation. Rev.A-treatment decreased the rate of re-expression of sIgM in A20-HL cells, the amount of Ag internalized via sIgM during 3 hours of incubation, and the generation of antigenic peptides from TNP-OVA internalized via sIgM. Rev.A-treatment was suggested to affect intracellular trafficking from early endosomes into late endocytic compartments of Ag internalized via sIgM. Rev.A might provide a useful tool for studying intracellular transport of Ag, especially Ag internalized via sIgM.

Reveromycin A Inhibits Antigen Receptor-mediated Antigen Presentation by B Lymphoma Cells via Its Effect on Intracellular Trafficking of the Antigen.